Search research articles
Contact Us
Filters
Showing results (151-160 of 189) with videos related to
Page
of 19
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 17, 2024
Safety, Efficacy, and Biomarker Analysis of Deulorlatinib (TGRX-326) in Anaplastic Lymphoma Kinase-Positive NSCLC: A Multicenter, Open-Label, Phase 1/1b Trial
Shen Zhao, Huaqiang Zhou, Nong Yang, et al.
BMC Medicine
|
April 29, 2023
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies
Xingsheng Hu, Shucai Zhang, Zhiyong Ma, et al.
Lancet (London, England)
|
January 16, 2026
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
Shun Lu, Jie Wang, Nong Yang, et al.
Translational Lung Cancer Research
|
May 19, 2020
Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort
Yong Song, Chengping Hu, Zhanhong Xie, et al.
The Lancet. Oncology
|
January 17, 2022
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
Qing Zhou, Ming Chen, Ou Jiang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 12, 2020
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)
Yunpeng Yang, Zhehai Wang, Jian Fang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 11, 2020
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial
James Chih-Hsin Yang, D Ross Camidge, Cheng-Ta Yang, et al.
Cancer Letters
|
November 24, 2025
A two-stage genome-wide association study to identify novel genetic loci associated with irAEs in lung cancer patients receiving PD-1/PD-L1 inhibitors
Lei She, Juan Chen, Jun-Yan Liu, et al.
Journal of the National Cancer Center
|
July 22, 2024
Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)
Jianchun Duan, Wenfeng Fang, Hairong Xu, et al.
Nature Communications
|
December 15, 2025
PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial
Liang Zeng, Zhaohui Ruan, Huan Yan, et al.
Page
of 19
Search research articles
Search
Showing results (151-160 of 189) with videos related to
Sort By:
Page
of 19
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 17, 2024
Safety, Efficacy, and Biomarker Analysis of Deulorlatinib (TGRX-326) in Anaplastic Lymphoma Kinase-Positive NSCLC: A Multicenter, Open-Label, Phase 1/1b Trial
Shen Zhao, Huaqiang Zhou, Nong Yang, et al.
BMC Medicine
|
April 29, 2023
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies
Xingsheng Hu, Shucai Zhang, Zhiyong Ma, et al.
Lancet (London, England)
|
January 16, 2026
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
Shun Lu, Jie Wang, Nong Yang, et al.
Translational Lung Cancer Research
|
May 19, 2020
Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort
Yong Song, Chengping Hu, Zhanhong Xie, et al.
The Lancet. Oncology
|
January 17, 2022
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
Qing Zhou, Ming Chen, Ou Jiang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 12, 2020
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)
Yunpeng Yang, Zhehai Wang, Jian Fang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 11, 2020
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial
James Chih-Hsin Yang, D Ross Camidge, Cheng-Ta Yang, et al.
Cancer Letters
|
November 24, 2025
A two-stage genome-wide association study to identify novel genetic loci associated with irAEs in lung cancer patients receiving PD-1/PD-L1 inhibitors
Lei She, Juan Chen, Jun-Yan Liu, et al.
Journal of the National Cancer Center
|
July 22, 2024
Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)
Jianchun Duan, Wenfeng Fang, Hairong Xu, et al.
Nature Communications
|
December 15, 2025
PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial
Liang Zeng, Zhaohui Ruan, Huan Yan, et al.
Page
of 19